IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients



Status:Archived
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2010
End Date:October 2012

Use our guide to learn which trials are right for you!

A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT


Study for the outcome and safety of individualized busulfan dosing with bortezomib for
patients preparing for a second stem cell transplant to treat multiple myeloma.


Evaluation of six-month response in relapsed multiple myeloma subjects, who have had a prior
autologous HSCT (greater than one year previously) receiving an IV busulfan-based
conditioning regimen with the combination of PK-guided IV busulfan dosing and bortezomib,
followed by a second autologous HSCT.

Assessment of the safety profile of this conditioning regimen will also be completed.


We found this trial at
4
sites
Salt Lake City, Utah 84112
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials